Best Medical Stocks To Follow Today – December 12th
by Danessa Lincoln · The Markets DailyEli Lilly and Company, UnitedHealth Group, Akero Therapeutics, Tilray Brands, and Pfizer are the five Medical stocks to watch today, according to MarketBeat’s stock screener tool. “Medical stocks” are publicly traded companies whose primary businesses are in healthcare and life sciences—including pharmaceuticals, biotechnology, medical device manufacturers, diagnostics, hospitals and health services, and health insurers. Investors in medical stocks typically evaluate factors like clinical trial results, regulatory approvals, patent protection, reimbursement policy, and demographic trends, and should be aware that these stocks can offer strong growth potential but often carry high regulatory and binary-event risk. These companies had the highest dollar trading volume of any Medical stocks within the last several days.
Eli Lilly and Company (LLY)
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
Read Our Latest Research Report on LLY
UnitedHealth Group (UNH)
UnitedHealth Group Incorporated operates as a diversified health care company in the United States. The company operates through four segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health care coverage, and health and well-being services to individuals age 50 and older addressing their needs; Medicaid plans, children's health insurance and health care programs; and health and dental benefits, and hospital and clinical services, as well as health care benefits products and services to state programs caring for the economically disadvantaged, medically underserved, and those without the benefit of employer-funded health care coverage.
Read Our Latest Research Report on UNH
Akero Therapeutics (AKRO)
Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.
Read Our Latest Research Report on AKRO
Tilray Brands (TLRY)
Tilray, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc. is headquartered in Canada.
Read Our Latest Research Report on TLRY
Pfizer (PFE)
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Read Our Latest Research Report on PFE
Featured Stories
- MarketBeat’s Top Five Stocks to Own in December 2025
- Broadcom Slips Post-Earnings Even as AI Demand Goes Parabolic
- Qualcomm Just Got Called an AI Loser—So Why Is It Rallying?
- 2 Small-Cap Biotechs That Could Reward Patient Investors
- Santa Claus May Be Coming Early for Palantir Investors
- 4 Canadian Oil Stocks That Are Filling the Heavy Crude Gap